• Eton Pharmaceuticals swung to third-quarter 2026 net income of $35.2 million from a year-earlier loss.
• Revenue more than doubled year over year to $57.9 million, driven by HEMANGEOL’s addition and higher sales across the portfolio.
• LIBERVANT is expected to launch in April 2027, subject to FDA approval.
• Full-year 2026 revenue guidance rose to more than $175 million from more than $145 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eton Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051605PRIMZONEFULLFEED9871591) on November 05, 2026, and is solely responsible for the information contained therein.